Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
LIVERMORE, Calif., July 25, 2013 /PRNewswire/ -- The Fibroid Treatment Collaborative, with centers in Chicago, IL and Austin TX, announced today the adoption of the Acessa Procedure as its primary surgical therapy for patients suffering from uterine fibroids. Traditional surgical interventions, such as hysterectomy or myomectomy, involve long recovery periods and other minimally invasive solutions may only treat symptoms, not the fibroids.
“Fibroids are highly-symptomatic; causing heavy menstrual bleeding, pain and pressure, and we’ve been waiting for a better minimally invasive solution,” said Abraham Shashoua, M.D., Director of the Fibroid Treatment Collaborative. “With Acessa, we can treat only the fibroids and resolve our patient’s symptoms in a same day surgery that has a rapid recovery period.”
The Acessa Procedure is a minimally invasive laparoscopic procedure that delivers radiofrequency energy to destroy the fibroids. After treatment, the fibroid is re-absorbed by the surrounding tissue. Acessa allows the surgeon to treat only the fibroids, while preserving normal function of the uterus. Patients typically go home the same day with little pain, and enjoy a rapid return to normal activities. More than 300 women have been successfully treated with Acessa.
“More than 7.5 million women in the U.S. with symptomatic fibroids reject the surgical options available to them for treatment of uterine fibroids,” said Jeffrey M. Cohen, Halt Medical CEO. “Hysterectomy is an over-used therapy that has many potential complications. Patients deserve an option that treats only the fibroids and allows them to get their lives back.”
About Halt Medical, Inc.
Founded in 2004, Halt Medical is a medical device company focused on establishing a new standard of care for women with symptomatic uterine fibroids. The Company has developed and launched the Acessa System and Procedure, using radiofrequency energy to destroy uterine fibroids. The results of both U.S. and international trials have led to the clearance of the product by the FDA for use in percutaneous, laparoscopic coagulation and ablation of soft tissue, including treatment of symptomatic uterine fibroids under laparoscopic ultrasound guidance. The Acessa System also has regulatory approval to treat symptomatic uterine fibroids in the European Union, Canada, and Mexico. The Company is located in Brentwood, CA. For information about the Acessa System, please visit www.haltmedical.com. To connect with Halt Medical on Facebook visit www.facebook.com/acessasystem or on Twitter at www.twitter.com/acessasystem.
About The Fibroid Treatment Collaborative
The physicians at The Fibroid Treatment Collaborative, Chicago Urogynecology, and Austin Urogynecology have more than 100 years of experience treating pelvic disorders. The Fibroid Treatment Collaborative is dedicated to the comprehensive multi-disciplinary approach to the management of uterine fibroids. The center provides unique and individualized treatment plans for patients. It is staffed by laparoscopic surgeons, radiologists, pain specialists, and physical therapists that work together to plan the best fibroid treatment. With a team approach to care, physicians, nurses and physical therapists apply their combined expertise in a range of conditions and therapies to provide individualized treatment for each patient. For more information, visit www.fibroid.com.
SOURCE Halt Medical, Inc.
Help employers find you! Check out all the jobs and post your resume.
